| Literature DB >> 31128298 |
Meran Keshawa Ediriweera1, Kamani Hemamala Tennekoon2, Sameera Ranganath Samarakoon2.
Abstract
Ovarian cancer (OC) is a lethal gynecological cancer. The phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) signaling pathway plays an important role in the regulation of cell survival, growth, and proliferation. Irregularities in the major components of the PI3K/AKT/mTOR signaling pathway are common in human cancers. Despite the availability of strong pre-clinical and clinical data of PI3K/AKT/mTOR pathway inhibitors in OC, there is no FDA approved inhibitor available for the treatment of OC. Here, we outline the importance of PI3K/AKT/mTOR signaling pathway in OC tumorigenesis, proliferation and progression, and pre-clinical and clinical experience with several PI3K/AKT/mTOR pathway inhibitors in OC.Entities:
Keywords: AKT; Ovarian cancer; PI3K; Pathway; mTOR
Mesh：
Substances：
Year: 2019 PMID： 31128298 DOI： 10.1016/j.semcancer.2019.05.012
Source DB: PubMed Journal: Semin Cancer Biol ISSN： 1044-579X Impact factor: 15.707